The agreement reflects Oncocyte's strategy to establish distribution partners with existing oncology channels to extend the reach of its tests globally.
The approach uses activity-based nanosensor technology being commercialized by spin-out Glympse Bio to detect dysregulated protease activity linked to disease.
Two recent acquisitions have resulted in the swift launch of two assays, one for the clinic and another for research use, as the firm's original test finally nears validation.
The company reported a net loss of $8.0 million, or $.15 per share, as it saw increased costs associated with its transition to commercial test provision.
